



Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors

Samuel J. Reddick¹ · Olivia Campagne¹ · Jie Huang² · Arzu Onar-Thomas² · Alberto Broniscer³ · Amar Gajjar³ · Clinton F. Stewart¹

Published online: 7 January 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to:
Cancer Chemotherapy and Pharmacology
(2019) 84:829–838
<https://doi.org/10.1007/s00280-019-03921-3>

[0-019-03921-3](https://doi.org/10.1007/s00280-019-03921-3). Epub 2019 Aug 7. PMID: 31392390 was not supported by NIH grant R25CA23944.

In the original publication of the article, the authors wish to note the following error:

Reddick et al. “Pharmacokinetics and Safety of Erlotinib and its Metabolite OSI-420 in Infants and Children with Primary Brain Tumors.” *Cancer Chemother Pharmacol.* 2019 Oct;84(4):829–838. <https://doi.org/10.1007/s00280-019-03921-3>

The original article can be found online at <https://doi.org/10.1007/s00280-019-03921-3>.

✉ Clinton F. Stewart
clinton.stewart@stjude.org

¹ Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-2794, USA

² Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN, USA

³ Division of Neuro-Oncology, Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA